TABLE 3.
PET Imaging and CSF-Derived Biologic Clearance Half-Lives of 124I-Omburtamab from CSF
| Mean |
Median |
||||||||||
| Parameter | Total median | 25% Q | 50% Q | 75% Q | Range | <5 y | 5–10 y | >10 y | <5 y | 5–10 y | >10 y |
| 124I-omburtamab PET | |||||||||||
| Ventricle | 8.19 | 6.61 | 8.89 | 9.57 | 3.6–18.2 | 9.22 | 8.62 | 8.81 | 8.14 | 8.3 | 9.01 |
| Cervical | 6.86 | 6.36 | 9.08 | 8.89 | 3.9–16.9 | 8.13 | 9.72 | 9.54 | 6.78 | 6.65 | 9.7 |
| Thoracic | 7.83 | 6.71 | 11.01 | 10.39 | 5.0–25.0 | 9.14 | 12.84 | 10.82 | 7.51 | 7.94 | 9.87 |
| Lumbar | 7.02 | 6.32 | 9.84 | 11.05 | 4.1–39.6 | 9.46 | 9.46 | 14.91 | 6.62 | 6.94 | 11.47 |
| 124I-omburtamab samples | 6.3 | 5.49 | 10.31 | 11.63 | 3.7–46.2 | 10.15 | 9.33 | 9.31 | 8.41 | 6.62 | 5.74 |
Q = quartile.
Data are in hours and exclude outliers 26 h and 44.4 h in single patient each.